An observational study in Osteoarthritis, Hip, Hip Disease and Hip Osteoarthritis, sponsored by MicroPort Orthopedics Inc.. Completed at 4 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2022-10-13.
Sponsored by MicroPort Orthopedics Inc. (part of MicroPort Scientific Corporation) · Observational
Among 155 studies in Osteoarthritis, Hip with a site in United States — 21 open to participants now, 32 under way, 1 of them phase 3. Osteoarthritis, Hip · United States.
Among the 155 studies in Osteoarthritis, Hip with a site in United States, this one is the 15th largest by enrollment of the 34 observational ones that give a count, is one of 14 that started in 2018, is one of 35 observational ones, and was the 74th registered.
641 studies on the registry are indexed under Osteoarthritis, Hip; 120 are open to participants now.
Browse Osteoarthritis, Hip studies →21 of the 155 studies in Osteoarthritis, Hip with a site in United States are open now. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18–75
Yale University · Sites in United States
Ages 18+
University of Sydney · Sites in United States, Australia
Ages 18+
Zimmer Biomet · Sites in United States
Ages 18+
F. Johannes Plate · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 87 Osteoarthritis, Hip studies recruiting now, 54 (62%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
155 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 14 · Phase 3 18 · Phase 4 9
First in 2001; this study’s year is marked. 14 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 173 is above the median of 135 across 158 observational studies indexed under Osteoarthritis, Hip.
Median enrollment 105 across the 118 interventional studies, 120 across the 34 observational. Of the 106 that completed or were terminated, 49 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 155 have an industry lead sponsor. The 10 most frequent:
This study is registered under MicroPort Orthopedics Inc., one of the names counted as MicroPort Scientific Corporation. Under that name alone:
MicroPort Orthopedics Inc. is the lead sponsor of 26 studies on the registry; 6 are open to participants now.
MicroPort Scientific Corporation has 1 study filed under Osteoarthritis, Hip — fewer than ten, so there is no comparison to draw.
5 of the studies in Osteoarthritis, Hip with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04990128Phase 3The Cleveland ClinicBone Marrow Aspirate Concentrate Versus Triamcinolone Injection For Hip Osteoarthritis | 2027-10 |
| NCT06778486University of California, DavisConversations in Health Literacy Using AI Technology for Osteoarthritis Patients | 2026-12 |
| NCT05675618Hospital for Special Surgery, New YorkReturn to Golf After Orthopaedic Surgery | 2026-12 |
| NCT04039386Michael C WilleyPsychosocial Interventions for Young Adults With Hip Pain | 2027-08-01 |
| NCT07104084F. Johannes PlateInfluence of Antiseptic Washes on Wound Healing Complications After THA | 2027-09-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 155 studies in Osteoarthritis, Hip with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is in response to the Food and Drug Administration (FDA) call to all manufacturers with 510(k) clearance for metal-on-metal (MoM) total hip arthroplasty (THA) devices to conduct postmarket surveillance studies. MicroPort has various acetabular shells, acetabular liners, fixation screws, femoral heads, femoral stems, modular necks, and proximal bodies currently cleared for MoM indications. Together these components comprise the Wright Medical Technology (WMT) MoM THA System. The primary objective of the study is to determine the incidence of adverse local tissue reactions (ALTR) in each THA implanted with the WMT MoM THA System overall and to create cross-sectional epochs of ≤ 8 years and > 8 years, since implantation.
Group 1: Subjects previously implanted with components of the Wright Medical Technology (WMT) Metal-on-Metal (MoM) Total Hip Arthroplasty (THA) System
Group 2: Control, non-implanted subjects
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be included in Group 1, subjects must meet all of the following criteria:
Has previously undergone primary THA for any of the following:
Previously implanted bilateral subjects can have both THAs enrolled in the study provided: 1) the specified combination of components were implanted in both, 2) all other aspects of the Inclusion/Exclusion Criteria are satisfied, 3) enrollment does not exceed the subject count specified in the Clinical Trial Agreement and protocol enrollment strategy, and 4) the subject agrees to a second Informed Consent document and data collection specific to the second THA. Enrollment and treatment of a previously unimplanted hip is not permitted in this study.
To be included in Group 2, subjects must meet all of the following criteria:
Exclusion Criteria:
Subjects will be excluded from either study group if they meet any of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects previously implanted with components of the Wright Medical Technology (WMT) Metal-on-Metal (MoM) Total Hip Arthroplasty (THA) System
Device: Wright Medical Technology Metal-on-Metal Total Hip System
Control, non-implanted subjects
Subjects in Group 1 previously implanted prior to the study start date will be identified from Investigator records. Collected data will be evaluated in aggregate and cross-sectioned by year of implantation. Subjects will be cross-sectioned by the time that has elapsed between implantation and the initial visit (e.g. 5 years, 6 years) using contiguous visit windows (number of years + 6 months). Subject data will be grouped in order to create cross-sectional epochs of ≤ 8 years and \> 8 years.
Rate of Adverse Local Tissue Reactions (ALTR)
To determine the incidence rate of ALTR in subjects implanted with WMT MoM THA System (Group 1)
Time frame: ≤ 8 years and > 8 years, since implantation
Determine chromium and cobalt whole blood and serum ion levels across time intervals
Cobalt and chromium metal ion levels will be measured in whole blood and serum from subjects implanted with the WMT MoM THA System (Group 1) at each defined cross-section interval.
Time frame: ≤ 8 years and > 8 years, since implantation
Establish baseline for chromium and cobalt whole blood and serum ion levels across time intervals
Analyze difference in chromium and cobalt whole blood and serum ion levels in subjects implanted with the WMT MoM THA System (Group 1) versus control subjects (Group 2) cross-sectionally.
Time frame: ≤ 8 years and > 8 years, since implantation
Compare functional outcomes of subjects implanted with the WMT MoM THA System with and without ALTR (Group-1 subjects).
Calculate and compare composite hip outcomes scores, via the validated HOOS scores, in Group 1 subjects with ALTR versus Group 1 subjects without ALTR
Time frame: ≤ 8 years and > 8 years, since implantation
Compare cobalt and chromium metal ion levels in subjects implanted with the WMT MoM THA System with and without ALTR (Group-1 subjects).
Analyze difference in cobalt and chromium metal ion levels from Group 1 subjects with ALTR versus Group 1 subjects without ALTR
Time frame: ≤ 8 years and > 8 years, since implantation
Ran from Apr 2018 to primary completion in Nov 2021, 43 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.